InnoPharmax
About
About Us
Organization
Our History
News
News
R&D
Pipeline
Anti-infection Agents
Contrast Agents
Oncology Agents
Immunological Agents
Drugs for Rare Diseases
Active Pharmaceutical Ingredient
Products
GemOral
N11005
Technologies
OralPAS®
OralPAS Pro®
MUCR™
Investors
Financial Information
Company Profile
Monthly Revenue
Financial Statements
Corporate Governance
Board Meeting
Committee
Internal Audit
Rule of Procedure
Corporate Social Responsibility
Shareholders Services
Annual Reports
Shareholders' Meetings
Announcements
Contact
Contacts
Contact Information
Career Opportunities
ZH-TW
Product and Pipeline
Pipeline
Anti-infection Agents
Contrast Agents
Oncology Agents
Immunological Agents
Drugs for Rare Diseases
Active Pharmaceutical Ingredient
Innomustine®(Bendamustine)
>
Oncology Agents
>
Product and Pipeline
>
home
Innomustine®(Bendamustine)
Innomustine
®
(Bendamustine)
Clicks:
8063
Bendamustine was synthesized to combine a purine and amino acid antagonist with an alkylating nitrogen mustard group (bifunctional alkylating agent). The major advantage of Bendamustine, compared to chlorambucil, is its favored water solubility. On the other hand, Bendamustine has been proven to be safe. It is indicated as single-agent therapy or in combination with other antineoplastic drugs for the treatment of the following malignancies: Hodgkin's disease (stages II-IV), non-Hodgkin's lymphoma (NHL), plasmocytoma; chronic lymphocytic leukaemia (CLL), and breast cancer. In March 25th, 2008,
INNOPHARMAX
has signed a license agreement with SymBio Pharmaceuticals Ltd. for the sublicense rights to Bendamustine HCl in Taiwan.
Back
uGear Design
-
Website Info.